XNAS · Healthcare · Biotechnology
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | -0.30 | -0.14 | +53.33% | $0 | ✅ Beat | -11.65% | +3.08% | +4.72% |
| 2026-03-13 | Q4 2025 | -0.37 | -0.27 | +27.03% | $0 | ✅ Beat | -15.00% | +0.16% | -12.56% |
| 2025-11-07 |
| Q3 2025 |
| -0.42 |
| -0.36 |
| +14.29% |
| $15.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-20 | Q4 2024 | -0.46 | -0.51 | -10.87% | $0 | ❌ Miss | -1.98% | +3.96% | -29.70% |
| 2024-05-13 | Q1 2024 | -0.54 | -0.40 | +25.93% | $0 | ✅ Beat | -1.07% | +2.30% | -18.98% |
| 2024-03-20 | Q4 2023 | -0.50 | -0.45 | +10.00% | $0 | ✅ Beat | — | — | — |
| 2023-08-10 | Q2 2023 | -0.55 | -0.62 | -12.73% | $334,000 | ❌ Miss | — | — | — |
| 2023-05-12 | Q1 2023 | -0.50 | -0.48 | +4.00% | $468,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.